Too much executive functioning is expected from ADHD-ers, ignoring key struggles of the disability. Colleges and universities ...

Exploring withdrawal risks, symptom variability, and safer discontinuation strategies Many people are surprised by how ...

New experiments reveal how astrocytes tune neuronal activity to modulate our mental and emotional states. The results suggest ...

Taking certain antidepressants at the time of a traumatic brain injury (TBI) is not associated with an increased risk of ...

The Prescription Drug User Fee Act target action date for the NDA is scheduled for 24 July 2026.

The MarketWatch News Department was not involved in the creation of this content.-- Centanafadine is an investigational compound for the treatment of ADHD in children, adolescents ...

Sleep apnea is a debilitating disease that many sufferers don’t even realize they have. Those afflicted with the condition ...

A new University of Manchester and Edinburgh study published in the journal Brain, Behavior and Immunity has found that ...

One minute, you’re swimming in the sparkling water off the Queensland coast. The next minute, you’re fighting for your life. That’s a plausible series of events for people unlucky enough to be stung ...

NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...

Many paediatric ICU (PICU) prescribers lacked knowledge about norepinephrine (NE) formulations they prescribed, creating risks in paediatric hypotensive shock. The self-reported nature of the survey ...

LOS ANGELES — The novel norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) centanafadine (Otsuka Pharmaceutical Co., Ltd.) is effective and ...